The Filing Desk

Fractyl Health

GUTS · Nasdaq · Health Care · Financials, fiscal 2023 to 2025

GUTS · Last close · November 19, 2026
$0.96
Value Fractyl Health yourself

Fractyl Health's revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$91 million. The diluted share count rose 74.1%.

Fractyl Health, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 24, 2026 · 0001193125-26-121793 Updated
Revenue
$0M
100.0%
Net margin
—
 
Net income
−$141M
 
Free cash flow
−$91M
 
Return on equity
−744.2%
 
Market cap
$13M
Nov 19 close
P/E
—
Loss: no P/E

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Gross margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Operating margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Net margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Free cash flow margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Fractyl Health does

Fractyl Health is developing treatments for obesity and type 2 diabetes that aim at what it sees as their root causes, rather than managing them with drugs taken for life. It is clinical-stage: none of its products is approved for sale in the United States, and it has earned revenue only in Germany, where it began a limited pilot launch of Revita in 2023.

Its lead product, the Revita system, is a procedure done through an endoscope that uses heat to resurface the lining of the duodenum, the first part of the small intestine. Fractyl is testing whether it helps people keep weight off after they stop taking GLP-1 weight loss drugs, which many patients quit. The U.S. Food and Drug Administration has given Revita Breakthrough Device status for that use, and Fractyl planned to ask the agency to approve it in late 2026. Its second program, Rejuva, is a gene therapy delivered to the pancreas with a single procedure, meant to make the body produce GLP-1 on its own; it is at an early stage. If Revita is approved, Fractyl would earn money from selling it, and doctors would need insurers to pay for the procedure.

The company is based in Burlington, Massachusetts, where it also assembles Revita. It had 100 full-time employees in March 2026, most of them in research and development.

Its biggest risks, as it describes them

  • Ongoing losses and a need for much more money to keep operating as a going concern.
  • Its studies may fail, be delayed or reveal serious side effects.
  • Revita may not win approval, and doctors may not use it unless insurers pay for the procedure.
  • Its loan agreement has terms that limit its flexibility.
  • Doing nearly all its research, manufacturing and storage at a single site.
From Fractyl Health's annual report on Form 10-K, filed March 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Fractyl Health lost money in fiscal 2025: a net loss of $141 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments336882
Debt incl. finance leases553031
Net debt (negative means net cash)22−37−51
Net debt to EBITDA———
Debt to equity—1.1x3.2x
Interest coverage−66.7x−29.9x−22.5x
Current ratio3.2x3.6x4.8x
Quick ratio3.2x3.6x4.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Fractyl Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Fractyl Health says to expect

  • Second quarter 2027: quarterly operating cash spendingAs cost reductions take effect and REMAIN-1 Pivotal Cohort expenditures decline, the Company expects quarterly operating cash spending to be reduced by approximately 50%, to approximately $8 million, by the end of Q2 2027.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 12, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 5 insiders bought $187,149 of Fractyl Health shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 14, 2026William BradleyDirectorBought64,516$0.62$40,000Form 4
Jun 12, 2026Ajay RoyanDirectorBought23,000$0.85$19,550Form 4
Jun 10, 2026William BradleyDirectorBought68,493$0.73$50,000Form 4
Jun 10, 2026Ian SheffieldDirectorBought35,000$0.73$25,550Form 4
Jun 10, 2026Harith RajagopalanChief Executive Officer, DirectorBought25,000$0.73$18,250Form 4
Jun 8, 2026Weber Lara SmithChief Financial OfficerBought20,000$0.69$13,800Form 4
Dec 4, 2025Harith RajagopalanChief Executive Officer, DirectorBought10,416$1.92$19,999Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score—3 of 8
Rule of 40−72,373.0%—
Altman Z''−14.81−16.47
Accruals ratio−3.4%−44.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positiveFailFail
Cash from operations is positiveFailFail
Return on assets rose—Fail
Cash from operations exceeds net incomePassPass
Debt fell relative to assets—Pass
Current ratio rosePassPass
Share count didn't riseFailFail
Gross margin rosePass—
Revenue rose relative to assets—Fail
F-score—3 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Fractyl Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Fractyl HealthFY25−100.0%————3
Abbott LaboratoriesFY255.7%18.2%16.7%11.2%0.4x6Compare
AdaptHealthFY25−0.5%2.8%6.8%2.1%3.5x4Compare
AngiodynamicsFY269.5%−12.5%0.2%−24.6%—4Compare
Anika TherapeuticsFY25−5.9%−9.8%3.9%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue000
Revenue growth—−22.5%−100.0%
Gross profit000
Research and development387074
Operating income−51−94−97
Net income−77−69−141
Diluted EPS (US$)−45.29−1.62−1.86
Diluted shares (millions)24476
Cash flow
Cash from operations−43−66−90
Capital expenditure021
Free cash flow−43−67−91
Dividends paid000
Share buybacks000
Acquisitions000
Stock-based compensation4147
Balance sheet at fiscal year end
Cash and short-term investments336882
Debt incl. finance leases553031
Total assets76108121
Total liabilities11480112
Shareholders' equity−3252810
Margins and ratios
Gross margin35.8%46.2%—
Operating margin−42,363.3%−100,571.0%—
Net margin−64,242.5%−73,864.5%—
Free cash flow margin−35,985.0%−72,350.5%—
Rule of 40 (growth + FCF margin)—−72,373.0%—
Return on capital———
Return on equity——−744.2%
Return on assets—−74.5%−122.8%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Fractyl Health's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Fractyl Health.